Pasadena Private Wealth LLC Cuts Stake in Harvard Bioscience, Inc. $HBIO

Posted by Brian Himes on May 30th, 2026

Pasadena Private Wealth LLC lowered its position in Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) by 81.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 45,000 shares of the medical instruments supplier’s stock after selling 198,911 shares during the period. Pasadena Private Wealth LLC’s holdings in Harvard Bioscience were worth $30,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of America Corp DE boosted its stake in Harvard Bioscience by 44.4% in the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after buying an additional 11,948 shares in the last quarter. Legato Capital Management LLC boosted its stake in Harvard Bioscience by 210.4% in the fourth quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 29,462 shares in the last quarter. Gamco Investors INC. ET AL purchased a new stake in Harvard Bioscience in the fourth quarter worth approximately $38,000. Jane Street Group LLC boosted its stake in Harvard Bioscience by 491.9% in the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 58,785 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Harvard Bioscience in the second quarter worth approximately $61,000. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Insider Buying and Selling

In other Harvard Bioscience news, Director Stephen J. Denelsky purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was bought at an average price of $4.87 per share, with a total value of $48,700.00. Following the completion of the purchase, the director directly owned 21,000 shares of the company’s stock, valued at $102,270. The trade was a 90.91% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO John D. Duke purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was acquired at an average cost of $5.01 per share, with a total value of $25,050.00. Following the purchase, the chief executive officer directly owned 105,000 shares of the company’s stock, valued at $526,050. This trade represents a 5.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 36,000 shares of company stock valued at $177,354 over the last quarter. 20.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the company. New Street Research set a $6.00 target price on Harvard Bioscience in a research note on Friday, March 13th. Wall Street Zen downgraded Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. Benchmark lowered their price objective on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a research report on Friday, March 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Harvard Bioscience has a consensus rating of “Hold” and an average price target of $6.00.

Read Our Latest Stock Report on HBIO

Harvard Bioscience Stock Performance

NASDAQ:HBIO opened at $5.88 on Friday. The firm has a market cap of $26.52 million, a PE ratio of -2.71 and a beta of 1.57. Harvard Bioscience, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $9.50. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.06 and a current ratio of 1.99. The business has a 50 day moving average price of $5.72 and a 200-day moving average price of $6.05.

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The medical instruments supplier reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.29. The firm had revenue of $20.76 million during the quarter, compared to analyst estimates of $21.20 million. Harvard Bioscience had a negative return on equity of 25.78% and a negative net margin of 11.44%.

Harvard Bioscience Profile

(Free Report)

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.